The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind,
![PDF] The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients | Semantic Scholar PDF] The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/6d41f362dc7966910bafe4967d3ff5ce6db0d400/2-Table2-1.png)
PDF] The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients | Semantic Scholar
![Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease - ScienceDirect Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0939641117313656-fx1.jpg)
Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease - ScienceDirect
![PDF) Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson`s disease patients PDF) Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson`s disease patients](https://www.researchgate.net/publication/303917064/figure/fig1/AS:443531878768647@1482757648461/Mean-parametric-maps-of-18-Ffallypride-BP-ND-in-a-group-of-nine-patients-with_Q320.jpg)
PDF) Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson`s disease patients
![Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease | Neurology Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease | Neurology](https://n.neurology.org/content/neurology/49/3/724/F2.large.jpg)
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease | Neurology
![The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study | Translational Neurodegeneration | Full Text The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study | Translational Neurodegeneration | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F2047-9158-3-11/MediaObjects/40035_2014_Article_78_Fig1_HTML.jpg)
The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study | Translational Neurodegeneration | Full Text
![PDF) Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson`s disease patients PDF) Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson`s disease patients](https://i1.rgstatic.net/publication/303917064_Occupancy_of_pramipexole_Sifrol_at_cerebral_dopamine_D23_receptors_in_Parkinsons_disease_patients/links/5861160d08ae6eb871a8595a/largepreview.png)